Abstract
Background: In 2008, the Heart Foundation published a minor position statement and supporting documents to recommend marine n-3 omega fatty acids (EPA), (DHA) in all patients with coronary disease and set targets of intake for asymptomatic individuals. Since thepublication new relevant trials have been published and other groups around the world have made recommendations. Methods:Reviewofpublishedarticles regardingmarine n-3 fatty acids and review of guidelines of other national bodies such as the National Institute of Health and Clinical Excellence (NICE) and the European Society of Cardiology. Results: Since the Heart Foundation review, two major outcome trials have been published. First, an underpowered post infarction trial from Germany involved 1000 i t w v p e t s t
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
